Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental Alzheimer's drug aims to lower brain 'Tangles' in Early-Stage patients

NCT ID NCT05469360

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a drug called NIO752 in 38 people with mild Alzheimer's or mild cognitive impairment due to Alzheimer's. The drug is given as one or two injections into the spinal fluid to see if it can lower levels of tau protein, a key marker of Alzheimer's damage. The main goal is to check safety and how well the drug works at reducing tau, not yet to improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
NIO752 (a drug injected into the spinal fluid to target tau protein)
What this could lead to
If successful, this could point toward a treatment that slows or stops Alzheimer's by reducing harmful tau protein buildup in the brain.
What could go wrong
This is a very early Phase 1 trial with only 38 participants, so it is primarily testing safety and dosing—not yet proven to help memory or thinking. The drug is injected into the spine, which carries risks like headache or infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease brain disorder central nervous system disorder cognitive disorder Cognitive Dysfunction dementia Memory Disorders nervous system disorder neurodegenerative disease tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT

Contacts and locations

Locations

  • Novartis Investigative Site

    Kuopio, 70210, Finland

  • Novartis Investigative Site

    Turku, 20520, Finland

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Valencia, Valencia, 46017, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Barcelona, 08041, Spain

  • Novartis Investigative Site

    Malmö, 221 85, Sweden

  • Novartis Investigative Site

    Stockholm, 141 86, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.